Key Points
- BeOne Medicines director Alessandro Riva sold 212 shares on May 22 at an average price of $309.51, totaling $65,616.12. The filing says the sale was made to cover tax withholding tied to vested equity awards.
- The company recently reported quarterly EPS of $0.25 on revenue of $1.51 billion, with net margin of 8.94% and return on equity of 12.06%. Analysts expect full-year EPS of 5.65.
- Wall Street remains broadly positive on BeOne Medicines, with an average rating of “Moderate Buy” and an average price target of $389.15. Institutional investors own 48.55% of the stock.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) Director Alessandro Riva sold 212 shares of the company's stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.51, for a total transaction of $65,616.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
BeOne Medicines Price Performance
NASDAQ:ONC opened at $300.01 on Thursday. The firm has a market cap of $32.92 billion, a price-to-earnings ratio of 67.12 and a beta of 0.50. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The company's 50-day moving average is $301.85 and its two-hundred day moving average is $321.12. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $235.57 and a 12-month high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The company had revenue of $1.51 billion during the quarter. Research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post 5.65 EPS for the current year.
Institutional Trading of BeOne Medicines
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mariner LLC increased its position in BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company's stock worth $269,000 after purchasing an additional 32 shares in the last quarter. Signaturefd LLC grew its position in BeOne Medicines by 10.7% in the fourth quarter. Signaturefd LLC now owns 340 shares of the company's stock valued at $103,000 after acquiring an additional 33 shares in the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company's stock valued at $66,000 after acquiring an additional 39 shares in the last quarter. CWM LLC grew its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Sequoia Financial Advisors LLC grew its position in BeOne Medicines by 4.1% in the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company's stock valued at $436,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently commented on the stock. Leerink Partners upped their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an "outperform" rating in a research note on Friday, May 15th. Wolfe Research assumed coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They set an "outperform" rating and a $340.00 price objective for the company. Guggenheim upped their price objective on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Jefferies Financial Group downgraded shares of BeOne Medicines from a "buy" rating to a "hold" rating and dropped their price objective for the company from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $423.00 to $425.00 and gave the company an "outperform" rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has an average rating of "Moderate Buy" and an average price target of $389.15.
Read Our Latest Report on BeOne Medicines
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
